Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480754 | 1.00 | KIF11 (0.48) | KIF11CYP19A1PDE5AALDH1A1NPC1 | |
| SCHEMBL3313044 | 0.91 | CYP19A1 (0.49) | KIF11CYP19A1PDE5ANPC1RAB9A | |
| SCHEMBL3314800 | 0.91 | CYP19A1 (0.49) | KIF11CYP19A1PDE5ANPC1RAB9A | |
| SCHEMBL3318086 | 0.91 | CYP19A1 (0.49) | KIF11CYP19A1PDE5ANPC1RAB9A | |
| SCHEMBL3318987 | 0.89 | CYP19A1 (0.47) | KIF11CYP19A1PDE5AALDH1A1NPC1 | |
| SCHEMBL3319768 | 0.89 | CYP19A1 (0.47) | KIF11CYP19A1PDE5AALDH1A1NPC1 | |
| SCHEMBL3321171 | 0.89 | CYP19A1 (0.47) | KIF11CYP19A1PDE5AALDH1A1NPC1 | |
| SCHEMBL3319653 | 0.89 | KIF11 (0.51) | KIF11CYP19A1PDE5AALDH1A1NPC1 | |
| SCHEMBL3318668 | 0.89 | KIF11 (0.51) | KIF11CYP19A1PDE5AALDH1A1NPC1 | |
| SCHEMBL4479844 | 0.89 | CYP19A1 (0.45) | KIF11CYP19A1PDE5AKCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595337-B2 | 2-Carbonyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole derivatives such as 2-acetyl-8-fluoro-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole and 3S,3aS)-2-acetyl-8-chloro-7-methyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole that are useful for treating cancer | MERCK & CO. INC. (US) | 2009-09-29 | — | — | US | claimed |
| US-20080182843-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-07-31 | — | — | US | claimed |
| US-7595337-B2 | 2-Carbonyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole derivatives such as 2-acetyl-8-fluoro-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole and 3S,3aS)-2-acetyl-8-chloro-7-methyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole that are useful for treating cancer | MERCK & CO. INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595337-B2 | 2-Carbonyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole derivatives such as 2-acetyl-8-fluoro-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole and 3S,3aS)-2-acetyl-8-chloro-7-methyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole that are useful for treating cancer | MERCK & CO. INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595337-B2 | 2-Carbonyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole derivatives such as 2-acetyl-8-fluoro-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole and 3S,3aS)-2-acetyl-8-chloro-7-methyl-3-phenyl-2,3,3a,4-tetrahydrochromeno[4,3-c]pyrazole that are useful for treating cancer | MERCK & CO. INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080182843-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-07-31 | — | — | US | disclosed |
| US-20080182843-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-07-31 | — | — | US | disclosed |
| US-20080182843-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182843-A1 | Mitotic Kinesin Inhibitors | KIF2C, KIF5B, KIF18B | KIF11 8/4885CYP19A1 3279/4885PDE5A 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.